| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5636 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2903 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1403 | 2021 |
| Chemokine receptors and their role in inflammation and infectious diseases C Murdoch, A Finn Blood, The Journal of the American Society of Hematology 95 (10), 3032-3043, 2000 | 1234 | 2000 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 978 | 2022 |
| Valganciclovir for symptomatic congenital cytomegalovirus disease DW Kimberlin, PM Jester, PJ Sánchez, A Ahmed, R Arav-Boger, ... New England Journal of Medicine 372 (10), 933-943, 2015 | 860 | 2015 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 807 | 2021 |
| Clinical spectrum of X-linked hyper-IgM syndrome J Levy, T Espanol-Boren, C Thomas, A Fischer, P Tovo, P Bordigoni, ... The Journal of pediatrics 131 (1), 47-54, 1997 | 771 | 1997 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 767 | 2021 |
| Interleukin-17A mediates acquired immunity to pneumococcal colonization YJ Lu, J Gross, D Bogaert, A Finn, L Bagrade, Q Zhang, JK Kolls, ... PLoS pathogens 4 (9), e1000159, 2008 | 577 | 2008 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 530* | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 516* | 2021 |
| Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised … X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, ... The Lancet 398 (10303), 856-869, 2021 | 515 | 2021 |
| Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass A Finn, S Naik, N Klein, RJ Levinsky, S Strobel, M Elliott The Journal of Thoracic and Cardiovascular Surgery 105 (2), 234-241, 1993 | 395 | 1993 |
| Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization … N Gossger, MD Snape, LM Yu, A Finn, G Bona, S Esposito, N Principi, ... Jama 307 (6), 573-582, 2012 | 371 | 2012 |
| Cxc chemokine receptor expression on human endothelial cells C Murdoch, PN Monk, A Finn Cytokine 11 (9), 704-712, 1999 | 347 | 1999 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 334 | 2021 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 330 | 2021 |
| Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial RC Read, D Baxter, DR Chadwick, SN Faust, A Finn, SB Gordon, ... The Lancet 384 (9960), 2123-2131, 2014 | 310 | 2014 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 284 | 2021 |
Professor Sir Andrew PollardUniversity of OxfordVerified email at paediatrics.ox.ac.uk
